Therefore, HIF-PH inhibitors hold a clinical use in elevating EPO levels and preventing damage related to ischemia-reperfusion such as cerebral ischemia, cardiac ischemia, and ischemic renal failure (Sulser et al., 2020). Here, EPO is linked to Cerebral ischemia.